Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Quint-Fonsegrives – page 91

1 508 clinical trials in Quint-Fonsegrives, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Quint-Fonsegrives at a glance
1 508
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 508 trials in Quint-Fonsegrives

Open in trial search

Glioblastoma multiforme

Not recruiting

Study of Berubicin versus lomustine in adult patients with recurrent Glioblastoma Multiforme after first-line treatment failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Cns Pharmaceuticals Inc.

Essential thrombocythaemia

Not recruiting

Study Comparing Bomedemstat and Hydroxycarbamide for Patients with Essential Thrombocythemia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat
  • Sponsor:Merck Sharp & Dohme LLC

Metastatic renal cell carcinoma

Not recruiting

Study of Axitinib and Pembrolizumab for Patients with Advanced or Metastatic Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Centre Leon Berard

Sarcoma

Not recruiting

Study on Advanced Soft-Tissue Sarcoma: Testing Futibatinib and Drug Combination for Patients with Unresectable or Metastatic Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capmatinib
  • Sponsor:Institut National De La Sante Et De La Recherche Medicale

Atrial fibrillation

Not recruiting

Study of rivaroxaban versus standard care in patients with excessive atrial ectopy or short atrial runs who have high risk of blood clots

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Lactose Monohydrate
  • Sponsor:Assistance Publique Hopitaux De Paris

Eosinophilic granulomatosis with polyangiitis

Not recruiting

Study on Mepolizumab and Drug Combination for Patients with Eosinophilic Granulomatosis with Polyangiitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Ischaemic stroke

Not recruiting

Study on Glenzocimab for Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glenzocimab
  • Sponsor:Assistance Publique Hopitaux De Paris

Gastric cancer+1

Not recruiting

Study of Zanidatamab and Tislelizumab Combined with Chemotherapy for Patients with Advanced or Metastatic HER2-positive Gastroesophageal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Sickle cell disease

Not recruiting

Study of Mitapivat for Patients with Sickle Cell Disease and Kidney Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Diffuse large B-cell lymphoma+1

Not recruiting

Study of Tazemetostat with R-CHOP for Newly Diagnosed Diffuse Large B Cell Lymphoma or High-Risk Follicular Lymphoma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Acute myeloid leukaemia

Not recruiting

Study on Venetoclax, Azacitidine, and Donor Lymphocyte Infusion for Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Relapse After Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Groupe Francophone Des Myelodysplasies

Head and neck cancer

Not recruiting

Study on Immunotherapy with Nivolumab and Ipilimumab for Patients with Recurrent Head and Neck Cancer After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Institut Gustave Roussy

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Quint-Fonsegrives

What the registry says about research in the country

01 Urological Research

Extensive research focusing on bladder cancer treatments, including innovative therapies for both muscle-invasive and non-muscle-invasive cases. Studies also address prostate conditions, from benign hyperplasia to advanced cancer.

  • Advanced bladder cancer treatments
  • Prostate cancer therapy optimization
  • Kidney stone management

Novel approaches combine immunotherapy with targeted treatments to improve patient outcomes.

02 Oncology Studies

Comprehensive research into breast cancer treatments, particularly focusing on triple-negative and hormone receptor-positive variants. Studies evaluate new approaches in colon cancer management using circulating tumor DNA analysis.

  • Triple-negative breast cancer therapy
  • Colorectal cancer treatment
  • Lung cancer interventions

Investigations combine immunotherapy with traditional treatments for enhanced efficacy.

03 Specialized Medicine

Research addressing pulmonary conditions and specialized medical needs. Studies include evaluation of treatments for chronic obstructive pulmonary disease and migraine management in emergency settings.

  • COPD treatment optimization
  • Migraine therapy
  • Diabetic eye conditions

Focus on improving patient quality of life through innovative therapeutic approaches.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.